Neuron-Specific Enolase (NSE) Panel
The NSE panel measures the levels of neuron-specific enolase, a glycolytic enzyme found in neurons and neuroendocrine cells, which can indicate the presence of certain cancers.
NSE is a biomarker used to diagnose and monitor neuroendocrine tumors and small cell lung cancer.
Key facts at a glance
- Units
- ng/mL
- Clinical utility
- diagnostic
- Result kind
- quantitative
- FDA-cleared
- Roche NSE, Abbott NSE, Fujirebio NSE
The Neuron-Specific Enolase (NSE) panel is a diagnostic test that quantifies the concentration of NSE in the blood. NSE is primarily found in neural tissue and neuroendocrine cells, making it a useful marker for conditions affecting these tissues.
Elevated levels of NSE are often associated with neuroendocrine tumors, small cell lung cancer (SCLC), and other neurological conditions. The test is particularly valuable for diagnosing and monitoring the progression of SCLC.
The reference range for NSE is typically between 0–17 ng/mL. Levels above this range may indicate the presence of a tumor or other pathological conditions, necessitating further investigation.
Frequently asked questions
What is the primary use of the NSE panel?
What do elevated NSE levels indicate?
Sources
- 1
- 2
Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy